title: [Omalizumab in the treatment of chronic urticaria: what's new in 2013?].
abstract: In 2013, new crucial data dealing with the treatment options for chronic idiopathic and physical urticaria have been published. In this article, after a short introduction where we discuss the classification and the pathogenesis of the disease, we will focus on the therapeutic approach in patients with chronic urticaria. In particular, considering the data available on the treatment with omalizumab, we will discuss the indications and treatment modalities of chronic urticaria.
authors.affiliation: Service d'immunologie et d'allergologie, Departement de médecine interne, HUG, 1211 Geneve. david.spoerl@hcuge.ch
authors.forename: David
authors.initials: D
authors.lastname: Spoerl
authors.affiliation: Service d'immunologie et d'allergologie, Departement de médecine interne, HUG, 1211 Geneve.
authors.forename: Thomas
authors.initials: T
authors.lastname: Harr
authors.affiliation: Service d'immunologie et d'allergologie, Departement de médecine interne, HUG, 1211 Geneve.
authors.forename: Jörg D
authors.initials: JD
authors.lastname: Seebach
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D002908:Chronic Disease; D003880:Dermatology / Q000379:methods / Q000639:trends; D006801:Humans; D000069444:Omalizumab; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab
vernacular_title: Allergologie. Omalizumab dans le traitement de l'urticaire chronique: quoi de neuf en 2013 ?